James Ermer

779 total citations
45 papers, 656 citations indexed

About

James Ermer is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, James Ermer has authored 45 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Psychiatry and Mental health, 12 papers in Cellular and Molecular Neuroscience and 10 papers in Pharmacology. Recurrent topics in James Ermer's work include Attention Deficit Hyperactivity Disorder (20 papers), Neurotransmitter Receptor Influence on Behavior (11 papers) and Estrogen and related hormone effects (7 papers). James Ermer is often cited by papers focused on Attention Deficit Hyperactivity Disorder (20 papers), Neurotransmitter Receptor Influence on Behavior (11 papers) and Estrogen and related hormone effects (7 papers). James Ermer collaborates with scholars based in United States, Canada and United Kingdom. James Ermer's co-authors include Patrick Martin, Danny D. Shen, Gary M. Pollack, Michael Pennick, Mary Corcoran, Mary Buckwalter, Glen Frick, Ben Adeyi, Michael L. Pucci and Paul T. Martin and has published in prestigious journals such as Journal of Neurology Neurosurgery & Psychiatry, Clinical Pharmacology & Therapeutics and Toxicology and Applied Pharmacology.

In The Last Decade

James Ermer

45 papers receiving 622 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Ermer United States 16 327 156 106 90 85 45 656
Ruth Gillham United Kingdom 15 461 1.4× 137 0.9× 378 3.6× 46 0.5× 67 0.8× 16 746
Dragoslav Sokić Serbia 14 361 1.1× 119 0.8× 198 1.9× 13 0.1× 84 1.0× 57 688
Shichuo Li China 15 454 1.4× 99 0.6× 345 3.3× 31 0.3× 51 0.6× 30 738
D Langer United States 14 561 1.7× 140 0.9× 577 5.4× 97 1.1× 134 1.6× 23 1.1k
José Rocha Portugal 14 332 1.0× 158 1.0× 236 2.2× 33 0.4× 47 0.6× 48 644
Paul Maertens United States 13 110 0.3× 96 0.6× 226 2.1× 16 0.2× 91 1.1× 36 773
Marisa Patrizia Messina Italy 16 69 0.2× 114 0.7× 174 1.6× 54 0.6× 45 0.5× 42 693
Patrick B. Kyle United States 17 35 0.1× 193 1.2× 108 1.0× 116 1.3× 31 0.4× 48 816
Hyun Jeong Han South Korea 16 243 0.7× 52 0.3× 22 0.2× 119 1.3× 59 0.7× 51 595
R. Tamura United States 8 865 2.6× 73 0.5× 55 0.5× 236 2.6× 36 0.4× 30 1.1k

Countries citing papers authored by James Ermer

Since Specialization
Citations

This map shows the geographic impact of James Ermer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Ermer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Ermer more than expected).

Fields of papers citing papers by James Ermer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Ermer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Ermer. The network helps show where James Ermer may publish in the future.

Co-authorship network of co-authors of James Ermer

This figure shows the co-authorship network connecting the top 25 collaborators of James Ermer. A scholar is included among the top collaborators of James Ermer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Ermer. James Ermer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ermer, James, Michael Pennick, & Glen Frick. (2016). Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy. Clinical Drug Investigation. 36(5). 341–356. 49 indexed citations
3.
Ermer, James, Mary Corcoran, & Patrick Martin. (2015). Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. Drugs in R&D. 15(2). 175–185. 16 indexed citations
4.
Knebel, William, Mary Corcoran, James Ermer, & Marc R. Gastonguay. (2015). Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients. Clinical Pharmacokinetics. 54(8). 875–883. 4 indexed citations
5.
Knebel, William, et al.. (2014). Population Pharmacokinetic/Pharmacodynamic Modeling of Guanfacine Effects on QTc and Heart Rate in Pediatric Patients. The AAPS Journal. 16(6). 1237–1246. 6 indexed citations
6.
Knebel, William, et al.. (2014). Modeling and simulation of the exposure–response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD. Journal of Pharmacokinetics and Pharmacodynamics. 42(1). 45–65. 3 indexed citations
7.
Martin, Patrick, Bryan Dirks, Lev Gertsik, et al.. (2014). Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia. Journal of Clinical Psychopharmacology. 34(6). 682–689. 14 indexed citations
8.
Häge, Alexander, Regina Dittmann, Michael Pennick, et al.. (2014). P.7.f.009 Lisdexamfetamine dimesylate: hydrolysis, pharmacokinetics and duration of therapeutic action in children and adolescents with ADHD. European Neuropsychopharmacology. 24. S733–S734. 1 indexed citations
9.
10.
Corcoran, Mary, et al.. (2013). Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release. Drugs in R&D. 13(1). 53–61. 13 indexed citations
11.
Corcoran, Mary E., et al.. (2013). Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate. Drugs in R&D. 13(2). 119–128. 15 indexed citations
12.
Ermer, James, et al.. (2013). Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. Neuropsychiatric Disease and Treatment. 9. 219–219. 17 indexed citations
13.
Ermer, James, W Döll, Patrick Martin, et al.. (2011). Pharmacokinetics of Lisdexamfetamine Dimesylate after Targeted Gastrointestinal Release or Oral Administration in Healthy Adults. Drug Metabolism and Disposition. 40(2). 290–297. 18 indexed citations
14.
Ermer, James, W Döll, Erik P. Sandefer, et al.. (2011). Intranasal versus Oral Administration of Lisdexamfetamine Dimesylate. Clinical Drug Investigation. 31(6). 357–370. 31 indexed citations
15.
Ermer, James, Ben Adeyi, & Michael L. Pucci. (2010). Pharmacokinetic Variability of Long-Acting Stimulants in the Treatment of Children and Adults with Attention-Deficit Hyperactivity Disorder. CNS Drugs. 24(12). 1009–1025. 32 indexed citations
16.
17.
Buckwalter, Mary, et al.. (2009). Effects of Omeprazole on the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Extended-Release Mixed Amphetamine Salts in Adults. Postgraduate Medicine. 121(5). 11–19. 29 indexed citations
18.
19.
Osman, Mohammed, Appavu Chandrasekaran, Kelvin Chan, et al.. (1998). Metabolic Disposition of14C‐Bromfenac in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 38(8). 744–752. 7 indexed citations
20.
Pollack, Gary M., et al.. (1985). Effects of route of administration and repetitive dosing on the disposition kinetics of di(2-ethylhexyl) phthalate and its mono-de-esterified metabolite in rats. Toxicology and Applied Pharmacology. 79(2). 246–256. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruth Gillham Breakdown of academic impact, for papers by Dragoslav Sokić Breakdown of academic impact, for papers by Shichuo Li Breakdown of academic impact, for papers by D Langer Breakdown of academic impact, for papers by José Rocha Breakdown of academic impact, for papers by Paul Maertens Breakdown of academic impact, for papers by Marisa Patrizia Messina Breakdown of academic impact, for papers by Patrick B. Kyle Breakdown of academic impact, for papers by Hyun Jeong Han Breakdown of academic impact, for papers by R. Tamura
Rankless by CCL
2026